Revive Therapeutics (TSXV:RVV, OTCQB:RVVTF) announced the results for the three and nine months ended March 31, 2017.

As quoted in the press release:

“I am pleased with the progress we have made in 2017 with respect to the advancement of the Phase 2 clinical study in Cystinuria and the expansion of our product pipeline in cannabinoids, more specifically with the business development activities that have taken place,” said Craig Leon, Chief Executive Officer of Revive.

Operational Highlights

  • During the three months ended March 31, 2017, the Company announced:
  • The Appointment of Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases;
  • The Appointment of Dr. Yanlin Wang, MD, PhD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Kidney Diseases;
  • The Initiation of a Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases;
  • A Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases;
  • The Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases;
  • The Appointment of Dr. Pritesh Kumar as Scientific Advisor for Cannabinoid-Based Therapeutics;
  • The Initiation of a Phase 2 Study of REV-004 (Bucillamine) in Cystinuria; and
  • The Engagement of Massachusetts General Hospital for Cystinuria Phase 2 Study.

Click here to read the full press release.

Source: New feed